Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Editorial Volume 4 Issue 3

Survey of HAART/ART in HIV/AIDS Patients

Rajeev R Shah1*, Tracy William2, Apoorwa Gupta3

1Professor and Head, Microbiology Department, PMCH, Udaipur, India
2William Dental Clinic, Peris, France
3Apollo Hospital, Indore, India

*Corresponding Author: Rajeev R Shah, Professor and Head, Microbiology Department, PMCH, Udaipur, India.

Received: December 24, 2019; Published: February 01, 2020

×

  The Human Immunodeficiency Virus (HIV) has changed from life threatening to chronic condition due to the almost universal use and accessibility of antiretroviral treatment (ART) among HIV patients. Antiretroviral (ARV) treatment works by suppressing the viral load and restoring the immune system. Once patients start Highly Active Antiretroviral Therapy (HAART), it is to be continued lifelong in spite of its many adverse side effects. Zidovudine (AZT) a nucleoside reverse transcriptase inhibitor is the first line antiretroviral regimen in India, and was the first break through in AIDS therapy in 1990. It is known to be associated with life threatening toxicity like anaemia.

×

References

×

Citation

Citation: Rajeev R Shah., et al. “Survey of HAART/ART in HIV/AIDS Patients". Acta Scientific Pharmaceutical Sciences 4.3 (2020): 01.



Member In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 15, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US